Nkarta Analyst Ratings
Analysts Have Conflicting Sentiments on These Healthcare Companies: Deciphera Pharmaceuticals (DCPH), Atara Biotherapeutics (ATRA) and Nkarta (NKTX)
Nkarta Analyst Ratings
Nkarta Analyst Ratings
Nkarta Inc. Buy Rating Affirmed Amidst Promising Clinical Studies and Robust Financial Health
Buy Rating Affirmed: Nkarta's NKX019 Shows Promise in Lupus Nephritis Clinical Trials
William Blair Remains a Buy on Nkarta (NKTX)
Nkarta Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Evolus (EOLS) and Nkarta (NKTX)
TD Cowen Reaffirms Their Buy Rating on Nkarta (NKTX)
Stifel Nicolaus Keeps Their Buy Rating on Nkarta (NKTX)
Nkarta Analyst Ratings
HC Wainwright & Co. Maintains Buy on Nkarta, Raises Price Target to $22
Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX), Dianthus Therapeutics (DNTH) and Eli Lilly & Co (LLY)
Nkarta's Strategic Pivot to NKX019 Spurs Buy Rating Amid Strong Financials and Promising Trial Prospects
Buy Rating for Nkarta: Promising Future for NKX019 in Autoimmune Disease Treatment
Nkarta's Strategic Focus and Financial Strength Underpin Buy Rating
Nkarta Analyst Ratings
Innovative NK-Cell Therapy: A Buy Rating for Nkarta's Groundbreaking Approach to Autoimmune Diseases
Nkarta Analyst Ratings